In Vivo Model Development for Myelodysplasia

Alfa Cytology offers a comprehensive in vivo animal model development service tailored for Myelodysplasia research. Leveraging a wide array of established and cutting-edge animal models, our platform enables pharmaceutical and academic partners to evaluate the efficacy, safety, and mechanism of novel therapeutics targeting myelodysplastic syndromes (MDS) and related hematological disorders. Our expertise spans multiple species and model types, ensuring that each project is matched with the most scientifically relevant and translationally meaningful system.

Myelodysplastic syndromes (MDS) are a heterogeneous group of clonal hematopoietic disorders characterized by ineffective hematopoiesis, cytopenias, and a risk of progression to acute myeloid leukemia. Animal models are indispensable tools for unraveling disease mechanisms and for preclinical assessment of therapies. At Alfa Cytology, we utilize a diverse spectrum of species, including zebrafish (Danio rerio), chicken (Gallus gallus), and predominantly mouse (Mus musculus) strains such as C57BL/6, B6.SJL-Ptprca Pepcb/BoyJ, CD45.1, NSG, NOD, NRGS, and others. These models recapitulate key genetic, cellular, and microenvironmental aspects of human MDS, providing robust platforms for translational research. Our models incorporate patient-derived xenografts, genetic modifications, allograft and xenograft systems, and chemical induction, ensuring relevance to human disease pathogenesis and therapeutic response.

Genetic Models

Genetic models involve the introduction of specific gene mutations, knockouts, or transgenes associated with human myelodysplasia into animal subjects, most commonly mice. Techniques include CRISPR/Cas9-mediated gene editing, transgenic expression (e.g., NUP98/HOXD13, SF3B1 K700E, S100a9), and conditional knockouts (e.g., Tet2, Ezh2, Diaph1, Pik3ca/b/d, Atg7). These models faithfully mimic the genetic landscape of MDS and allow the study of disease initiation, progression, and therapeutic intervention. Advantages include precise control over genetic background and the ability to dissect gene-specific contributions to pathogenesis. Primary applications are mechanistic studies, biomarker discovery, and preclinical drug testing.

Xenograft and Patient-Derived Xenograft (PDX) Models

Xenograft and PDX models involve transplantation of human MDS cells, hematopoietic stem/progenitor cells, or iPSCs into immunodeficient mice (e.g., NSG, NOD, NRGS, NDG strains). These models reproduce the human disease microenvironment and cellular heterogeneity, supporting the engraftment and propagation of patient-derived cells. PDX models are especially valuable for evaluating personalized therapeutic responses and resistance mechanisms. Key advantages include high translational relevance and the ability to test human-specific therapeutics. Applications include efficacy and safety testing, biomarker validation, and co-clinical trial modeling.

Allograft and Syngeneic Models

Allograft and syngeneic models utilize transplantation of genetically modified or wild-type murine hematopoietic cells into recipient mice, often following irradiation to enable engraftment. These systems (e.g., CD45.1/CD45.2 marker systems, NUP98/HOXD13-transgenic donors) allow for controlled experimental manipulation and immune-competent settings. They are ideal for studying cell-intrinsic versus microenvironmental contributions to MDS, immune interactions, and for evaluating immunomodulatory therapies. Advantages include reproducibility, scalability, and compatibility with a wide range of genetic backgrounds. Research applications encompass mechanistic studies, drug screening, and immune-oncology investigations.

Chemically-Induced Models

Chemically-induced models use agents such as busulfan and fludarabine phosphate to induce myelodysplastic-like changes in hematopoietic tissues. These models are useful for studying environmental and drug-induced pathogenesis, as well as for preconditioning recipients for transplantation. The primary advantages are simplicity, cost-effectiveness, and rapid induction of disease phenotypes. Applications include toxicology, drug resistance, and combinatorial therapy studies.

Other Species Models (Zebrafish and Chicken)

Non-murine models, including zebrafish (Danio rerio) allografts of c-Myb-overexpressing cells and chicken (Gallus gallus) xenografts of human micromegakaryocytes, provide complementary systems for high-throughput screening and developmental biology studies. Zebrafish models offer optical transparency and genetic tractability, while chicken embryos support rapid engraftment and observation. These models are advantageous for early-stage drug screening, mechanistic exploration, and cross-species validation.

Alfa Cytology delivers a full-spectrum solution for in vivo myelodysplasia model development, from model selection and customization to comprehensive study execution and data analysis. Our services include sourcing and breeding of specialized strains, genetic engineering, irradiation and transplantation protocols, and engraftment of patient-derived or genetically modified cells. We offer a wide range of efficacy endpoints, including hematological profiling (CBC, differential counts), bone marrow histopathology, flow cytometry (e.g., CD45.1/CD45.2 chimerism), molecular analyses (qPCR, NGS), survival and disease progression metrics, and response to therapeutic interventions. Our advanced analytical capabilities encompass single-cell sequencing, immunophenotyping, and digital pathology. Rigorous quality control measures are implemented at every stage, including genetic validation, engraftment verification, health monitoring, and standardized protocols to ensure reproducibility and data integrity.

Partnering with Alfa Cytology empowers your myelodysplasia research with validated, translationally relevant animal models and expert scientific support. Our integrated platform accelerates your preclinical pipeline, reduces risk, and maximizes the predictive value of your studies. We are committed to scientific excellence, transparency, and client-focused collaboration. Contact us today to discuss your project needs and discover how our tailored in vivo models can advance your MDS research objectives.